Menu

Skip to content
  • For patients
    • Benefits
    • Area of application
    • Procedure & costs
  • MARK53 Knowledge
    • The biomarker
    • For all types of cancer
    • The Mark53 analysis
    • Quality assurance
  • Mark53 Studies
    • Colorectal cancer
    • Liver metastases
    • Oesophageal cancer
    • Biomarker studies
  • Press review
    • Press review 2016
    • Press review 2015
    • Press review 2014
    • Press review 2013
    • Press review 2002
  • MARK53-findings
    • MARK53-Board
    • MARK53 affiliated doctors
  • About us
    • Contact
    • Press kit
  • Request Mark53

Cancer therapy: more efficient – less side effects

Press kit

Here you’ll find our press documents for downloading, as well as current press and congress dates.

Press kit Austrian Surgeon Congress 29. of May 2013

  • Deutsch
  • English

ABOUT MARK53

With the Mark53 analysis, our company is making available a precise p53 gene test, which – for the first time – establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry.

  • For patients
    • Benefits
    • Area of application
    • Procedure & costs
  • MARK53 Knowledge
    • The biomarker
    • For all types of cancer
    • The Mark53 analysis
    • Quality assurance
  • Mark53 Studies
    • Colorectal cancer
    • Liver metastases
    • Oesophageal cancer
    • Biomarker studies
  • Press review
    • Press review 2016
    • Press review 2015
    • Press review 2014
    • Press review 2013
    • Press review 2002
  • MARK53-findings
    • MARK53-Board
    • MARK53 affiliated doctors
  • About us
    • Contact
    • Press kit
  • Request Mark53
  • Contact
  • Imprint
  • Partners
© 2013–2020 p53 research. All rights reserved
Diese Website benutzt Cookies. Wenn Sie die Website weiter nutzen, gehen wir von Ihrem Einverständnis aus.OK